Increased Cancer Risk & Effectiveness Concerns Prompt EU-Wide Review Of Preterm Birth Medicine

 
• By Vibha Sharma

The European Medicines Agency is re-examining the benefits and risks of hydroxyprogesterone medicines for gynecologic and obstetrical conditions at the request of the French regulator ANSM.

Premature newborn baby girl in the hospital incubator after c-section in 33 week
Hydroxyprogesterone caproate is given to prevent pregnancy loss or premature birth • Source: Shutterstock

More from Europe

More from Geography